“..we discuss strategies to reduce the risk in Phase 2 [clinical trials] due to addressing unprecedented targets. These strategies are designed to 1. Identify those targets that have the best chance of success in the discovery phase, and 2. employ early stage proof-of-concept (POC) clinical trials to weed out drugs and targets that do not achieve POC. The general strategy proposed in this report thus involves both improving the drug discovery and preclinical phases, and improving early development.”
Approaches to Reducing
Phase II Attrition, 2009.